Rosiglitazone alleviates injury in rats with adenine-induced chronic kidney disease

Molecular Medicine Reports

Volumn 8, Issue 6, 2013, Pages 1831-1835

  Huang, Ying ^a   Lei, Yan ^a   Zheng, Zhihua ^a   Wang, Xiaohua ^a   Hu, Mingliang ^a   Liu, Rongjun ^a   Yu, Xueqing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chronic kidney disease; Phosphate parathyroid hormone fibroblast growth factor 23 system; Proteinuria; Renal function; Rosiglitazone

Indexed keywords

ADENINE; CALCIUM; CREATINE; FIBROBLAST GROWTH FACTOR 23; NITROGEN; PARATHYROID HORMONE; PHOSPHATE; ROSIGLITAZONE; UREA; URIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CREATININE; FIBROBLAST GROWTH FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG EFFECT; KIDNEY DISTAL TUBULE; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PARENCHYMA; KIDNEY PROXIMAL TUBULE; MALE; MONOCYTE; NONHUMAN; PROTEIN URINE LEVEL; PROTEINURIA; RAT; RENAL PROTECTION; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; URINALYSIS; ANIMAL; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; KIDNEY FUNCTION TEST; KIDNEY TUBULE; PATHOLOGY; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; STAINING;

ADENINE; ANIMALS; CREATININE; FIBROBLAST GROWTH FACTORS; KIDNEY FUNCTION TESTS; KIDNEY TUBULES; MALE; PARATHYROID HORMONE; PHOSPHATES; PROTEINURIA; RATS; RENAL INSUFFICIENCY, CHRONIC; STAINING AND LABELING; THIAZOLIDINEDIONES;

EID: 84893765587     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1715     Document Type: Article

References (23)

1. Bello AK, Hemmelgarn B, Lloyd A, James MT, Manns BJ, Klarenbach S, et al: Associations among estimated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes. Clin J Am Soc Nephrol 6: 1418-1426, 2011.
2. Sarnak MJ and Astor BC: Implications of proteinuria: CKD progression and cardiovascular outcomes. Adv Chronic Kidney Dis 18: 258-266, 2011.
3. Faul C: Fibroblast growth factor 23 and the heart. Curr Opin Nephrol Hypertens 21: 369-375, 2012.
4. Nakano C, Hamano T, Fujii N, Obi Y, Matsui I, Tomida K, et al: Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis. Bone 50: 1266-1274, 2012.
5. Razzaque MS and Lanske B: The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 194: 1-10, 2007.
6. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, TakeuchiY, Fujita T, et al: Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113: 561-568, 2004.
7. Seiler S, Heine GH and Fliser D: Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int Suppl 76: S34-S42, 2009.
8. El-Abbadi MM, Pai AS, Leaf EM, Yang HY, Bartley BA, Quan KK, et al: Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int 75: 1297-1307, 2009.
9. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592, 2008.
10. Sharma SK, Zou H, Togtokh A, Ene-Iordache B, Carminati S, Remuzzi A, et al: Burden of CKD, proteinuria, and cardiovascular risk among Chinese, Mongolian, and Nepalese participants in the International Society of Nephrology screening programs. Am J Kidney Dis 56: 915-927, 2010.
11. Reel B, Guzeloglu M, Bagriyanik A, Atmaca S, Aykut K, Albayrak G and Hazan E: The effects of PPAR-γ agonist pioglitazone on renal ischemia/reperfusion injury in rats. J Surg Res 182: 176-184, 2013.
12. Basturk T, Unsal A, Ulas T, Koc Y, Sakaci T, Ahbap E and Borlu F: Effects of rosiglitazone treatment on insulin resistance and TNF-alpha levels in patients with chronic kidney disease: a prospective study. Eur Rev Med Pharmacol Sci 16: 1519-1524, 2012.
13. Setti G, Hayward A, Dessapt C, Barone F, Buckingham R, White K, et al: Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes. Am J Nephrol 32: 393-402, 2010.
14. Ren L, Liu N, Zhi H, Li Y, Li Y, Tang R, et al: Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro. Cardiovasc Diabetol 10: 10, 2011.
15. Alessi A, França Neto OR, Prim C, Silva RF, Noronha Ld, Brofman PR, et al: Rosiglitazone and vascular injury in hypercholesterolemic rabbits: neointimal formation assessment. Arq Bras Cardiol 95: 283-288, 2010.
16. Nakaya H: Roles of PPARgamma in preventing the development of atherosclerosis in LDL receptor null mice. Nihon Rinsho 68: 229-234, 2010 (In Japanese).
17. Schiffrin EL: Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol Heart Circ Physiol 288: H1037-H1043, 2005.
18. Hu W, Yu Q, Zhang J and Liu D: Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of Chemerin and ChemR23 in the kidney of streptozotocin-induced diabetic rats. Inflammation 35: 1287-1293, 2012.
19. Bergwitz C and Jüppner H: Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 61: 91-104, 2010.
20. Pontoriero G, Cozzolino M, Locatelli F and Brancaccio D: CKD patients: the dilemma of serum PTH levels. Nephron Clin Pract 116: c263-c268, 2010.
21. Levin A, Djurdjev O, Beaulieu M and Er L: Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis 52: 661-671, 2008.
22. Kincaid-Smith P, Fairley KF, Farish S, Best JD and Proietto J: Reduction of proteinuria by rosiglitazone in non-diabetic renal disease. Nephrology (Carlton) 13: 58-62, 2008.
23. Betz B, Schneider R, Kress T, Schick MA, Wanner C and Sauvant C: Rosiglitazone affects nitric oxide synthases and improves renal outcome in a rat model of severe ischemia/reperfusion injury. PPAR Res 2012: 219319, 2012.